From 2021 to 2022, medications to treat opioid use disorder (MOUD) increased 104%; from 2020 to 2021, it increased 1.6%. The AMA urges removal of all barriers to MOUD and greater removal of laws to ensure equitable, affordable access to MOUD.

Data source: IQVIA Xponent limited to retail pharmacy dispensed prescriptions; USC 78340 (drug dependency), which includes molecules buprenorphine (except where indicated for pain management in USC 02200), buprenorphine/naloxone, naltrexone.